Internal Medicine

Questions discussed in this category

What work up do you pursue for a thorough evaluation in patients that present with a potential diagnosis of dermatitis artefacta?

1 Answer available

What are standard selection criteria for patients who are eligible for heart transplantation?

1 Answer available

For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?

1 Answer available

What treatment combination approach would you recommend for mucous membrane pemphigoid?

2 Answers available

Do you use dual anti-platelet therapy inpatients with low NIHSS who have had bilateral brainstem strokes?

1 Answer available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Obinutuzumab in Lupus Nephritis

2 Answers available

Papers discussed in this category

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Annals of the rheumatic diseases, 2021 Oct 06

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.

The New England journal of medicine, 2025 Feb 07

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Stroke, 2013-12

CHANCE trial: early short-term dual antiplatelet treatment for stroke prevention.

The New England journal of medicine, 2014-09-11

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Circulation, 2022 Apr 01

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

The New England journal of medicine, 2019 Sep 19

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

The New England journal of medicine, 2020 Aug 28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Related Topics